Advertisement

Acta Neuropathologica

, Volume 129, Issue 1, pp 147–149 | Cite as

Oligoastrocytomas: throwing the baby out with the bathwater?

  • Paul Wilcox
  • Cheryl C. Y. Li
  • Maggie Lee
  • Brindha Shivalingam
  • Jeffrey Brennan
  • Catherine M. Suter
  • Kimberley Kaufman
  • Trina Lum
  • Michael E. Buckland
Correspondence

Recently in this journal, Sahm and colleagues advised “parting with the diagnosis of OA (oligoastrocytoma)”, based on genetic analyses of 43 putative OA tumours [4]. Here we present our viewpoint that the majority of tumours tested by Sahm et al. were not true OAs, and that the entity of OA, whilst uncommon, remains a valuable diagnosis. We describe two cases of OA that exhibit lineage-associated molecular alterations restricted to only a proportion of tumour cells. These cases demonstrate that molecular heterogeneity in a subset of OAs is real, with important implications for our understanding of fundamental glioma biology, clinical trial design, and future treatment decisions. OA should not be ignored in the proposed new classification guidelines [2].

Sahm and colleagues studied 43 cases diagnosed as OA based on histology. But in 30 of these cases, immunostaining for IDH1 (R132H) mutation was restricted to oligodendroglial areas only. The astrocytic component of these tumours was...

Keywords

TP53 Mutation Mutant IDH1 Oligodendroglial Tumour Molecular Heterogeneity Mixed Glioma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Conflict of interest

None.

Supplementary material

401_2014_1353_MOESM1_ESM.pdf (2.8 mb)
Supplementary material 1 (PDF 2851 kb)

References

  1. 1.
    Liu XY et al (2012) Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol 124(5):615–625. doi: 10.1007/s00401-012-1031-3 PubMedCrossRefGoogle Scholar
  2. 2.
    Louis DN et al (2014) International Society of Neuropathology-Haarlem Consensus Guidelines, for Nervous System Tumor Classification and Grading. Brain Pathol. doi: 10.1111/bpa.12171 Google Scholar
  3. 3.
    Qu M et al (2007) Genetically distinct astrocytic and oligodendroglial components in oligoastrocytomas. Acta Neuropathol 113(2):129–136PubMedCrossRefGoogle Scholar
  4. 4.
    Sahm F et al (2014) Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathol 128(4):551–559. doi: 10.1007/s00401-014-1326-7 PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Paul Wilcox
    • 1
  • Cheryl C. Y. Li
    • 1
    • 2
  • Maggie Lee
    • 1
    • 2
  • Brindha Shivalingam
    • 3
  • Jeffrey Brennan
    • 3
  • Catherine M. Suter
    • 4
  • Kimberley Kaufman
    • 1
    • 2
  • Trina Lum
    • 5
  • Michael E. Buckland
    • 1
    • 2
  1. 1.Brain and Mind Research InstituteUniversity of SydneyCamperdownAustralia
  2. 2.Department of NeuropathologyRoyal Prince Alfred HospitalCamperdownAustralia
  3. 3.Department of NeurosurgeryRoyal Prince Alfred HospitalCamperdownAustralia
  4. 4.Victor Chang Cardiac Research InstituteDarlinghurstAustralia
  5. 5.Department of Tissue Pathology and Diagnostic OncologyRoyal Prince Alfred HospitalCamperdownAustralia

Personalised recommendations